Intravenous milrinone in treatment of advanced congestive heart failure

Texas Heart Institute Journal

Volumn 30, Issue 2, 2003, Pages 109-113

  Zewail, Aly M ^a   Nawar, Mohammad ^a   Vrtovec, Bojan ^a   Eastwood, Cathy ^a   Kar, Biswajit ^a   Delgado III, Reynolds M ^a  

^a NONE

Author keywords

Adrenergic beta antagonists; Heart failure, congestive; Milrinone

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; MILRINONE; PHOSPHODIESTERASE INHIBITOR;

ADULT; ARTICLE; CAUSE OF DEATH; CONGESTIVE HEART FAILURE; DISEASE COURSE; DISEASE SEVERITY; DOSE CALCULATION; DRUG FATALITY; DRUG TOLERABILITY; FEMALE; HEART DEATH; HEART EJECTION FRACTION; HEMODYNAMICS; HOSPITAL ADMISSION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; INFUSIONS, INTRAVENOUS; LENGTH OF STAY; MALE; MIDDLE AGED; MILRINONE; PHOSPHODIESTERASE INHIBITORS; RETROSPECTIVE STUDIES;

EID: 0038315449     PISSN: 07302347     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. Am J Cardiol 1999;83(2A):1A-38A.
2. Ghali JK, Pina IL, Gottlieb SS, Deedwania PC, Wikstrand JC, MERIT-HF Study Group. Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). Circulation 2002;105 (13):1585-91.
3. Mehra MR, Ventura HO, Kapoor C, Stapleton DD, Zimmerman D, Smart FW. Safety and clinical utility of long-term intravenous milrinone in advanced heart failure. Am J Cardiol 1997;80:61-4.
4. Galinier M, Albenque JP, Afchar N, Fourcade J, Massabuau P, Doazan JP, et al. Prognostic value of late potentials in patients with congestive heart failure. Eur Heart J 1996;17:264-71.
5. Stegmayr BG, Banga R, Lundberg L, Wikdahl AM, Plum-Wirell M. PD treatment for severe congestive heart failure. Perit Dial Int 1996;16(Suppl 1):S231-5.
6. Campana C, Gavazzi A, Berzuini C, Larizza C, Marioni R, D'Armini A, et al. Predictors of prognosis in patients awaiting heart transplantation. J Heart Lung Transplant 1993; 12:756-65.
7. Young JB, Moen EK. Outpatient parenteral inotropic therapy for advanced heart failure. J Heart Lung Transplant 2000;19(8 Suppl):S49-57.
8. Skoyles JR, Sherry KM, Price C. Intravenous milrinone in patients with severe congestive cardiac failure awaiting heart transplantation. J Cardiothorac Vasc Anesth 1992;6:222-5.
9. Cesario D, Clark J, Maisel A. Beneficial effects of intermittent home administration of the inotrope/vasodilator milrinone in patients with end-stage congestive heart failure: a preliminary study. Am Heart J 1998;135:121-9.
10. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991;325:1468-75.
11. Jaski BE, Fifer MA, Wright RF, Braunwald E, Colucci WS. Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside. J Clin Invest 1985;75:643-9.
12. Monrad ES, Baim DS, Smith HS, Lanoue A, Brauwald E, Grossman W. Effects of milrinone on coronary hemodynamics and myocardial energetics in patients with congestive heart failure. Circulation 1985;71:972-9.
13. Benotti JR, Lesko LJ, McCue JE, Alpert JS. Pharmacokinetics and pharmacodynamics of milrinone in chronic congestive heart failure. Am J Cardiol 1985;56:685-9.
14. Bohm M. Alteration of beta-adrenoceptor-G-protein-regulated adenyl cyclase in heart failure. Mol Cell Biochem 1995;147:147-60.
15. Bohm M, Gierschik P, Jakobs KH, Pieske B, Schnabel P, Ungerer M, Erdmann E. Increase of Gi alpha in human hearts with dilated but not ischemic cardiomyopathy. Circulation 1990;82:1249-65.
16. Neumann J, Schmitz W, Scholz H, von Meyerinck L, Doring V, Kalmar P. Increase in myocardial Gi-proteins in heart failure. Lancet 1988;2:936-7.
17. Reithmann C, Gierschik P, Sidiropoulos D, Werdan K, Jakobs KH. Mechanism of noradrenaline-induced heterologous desensitization of adenylate cyclase stimulation in rat heart muscle cells: Increase in the level of inhibitory G-protein alpha-subunits. Eur J Pharmacol 1989;172:211-21.
18. Bohm M, Deutsch HJ, Hartmann D, Rosee KL, Stablein A. Improvement of postreceptor events by metoprolol treatment in patients with chronic heart failure. J Am Coll Cardiol 1997;30:992-6.
19. Heilbrunn SM, Shah P, Bristow MR, Valantine HA, Ginsburg R, Fowler MB. Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation 1989;79:483-90.
20. Gilbert EM, Olsen SL, Renlund DG, Bristow MR. betaadrenergic receptor regulation and left ventricular function in idiopathic dilated cardiomyopathy. Am J Cardiol 1993; 71:23C-29C.
21. Goldstein RA, Geraci SA, Gray EL, Rinkenberger RL, Dougherty AH, Naccarelli GV. Electrophysiologic effects of milrinone in patients with congestive heart failure. Am J Cardiol 1986;57:624-8.